Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice

  title={Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice},
  author={Taku Nagai and Yukihiro Noda and Teruaki Une and Kiyoshi Furukawa and Hiroshi Furukawa and Quan Kan and Toshitaka Nabeshima},
The antipsychotic efficacy of AD-5423, which has the properties of both a serotonin 5-HT2 and a dopamine D2 receptor antagonist, was evaluated using animal models of schizophrenia. Sensitization to phencyclidine (PCP)-induced hyperlocomotion is considered a model of the positive symptoms of schizophrenia, and was significantly antagonized by AD-5423 and haloperidol. The PCP-induced enhancement of immobility induced by the forced swimming test, a model of the negative symptoms of schizophrenia… 

PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments

Whether schizophrenia-related behaviors are differentially induced by acute and subchronic phencyclidine (PCP) treatment in mice and the neurobiological bases of these differences are examined to examine their different behavioral effects.

Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats

The results indicate that cannabis may exert protective effects on positive schizotypic symptoms in adult animals such as hypermotility and anxiety state and confirm that motivational effects were not responsible for the ameliorative effects of cannabinoids.

Prenatal exposure to phencyclidine produces abnormal behaviour and NMDA receptor expression in postpubertal mice.

Prenatal exposure to PCP produced long-lasting behavioural deficits, accompanied by the abnormal expression and dysfunction of NMDA receptors in postpubertal mice, which were attenuated by atypical antipsychotic treatment.

Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin

Preclinical behavioral models for predicting antipsychotic activity.


It is concluded that, with notable exceptions (attention, learning /memory, EPS liability), current predictive models for antipsychotics fall short of clear translational validity.

Blonanserin Ameliorates Phencyclidine-Induced Visual-Recognition Memory Deficits: the Complex Mechanism of Blonanserin Action Involving D3-5-HT2A and D1-NMDA Receptors in the mPFC

The results suggest that the ameliorating effect of blonanserin on PCP-induced cognitive impairment is associated with indirect functional stimulation of the dopamine-D1-PKA-NMDA receptor pathway following augmentation of dopaminergic neurotransmission due to inhibition of both dopamine- D3 and serotonin 5-HT2A receptors in the mPFC.



Atypical antipsychotic effects of quetiapine fumarate in animal models.

The effects of quetiapine fumarate in animal models of schizophrenia indicated its clinical effect on schizophrenia with a reduced liability to produce EPSE.

Recent advances in the phencyclidine model of schizophrenia.

It was found that PCP-induced psychotomimetic effects are associated with submicromolar serum concentrations of PCP and the findings suggest that endogenous dysfunction of NMDA receptor-mediated neurotransmission might contribute to the pathogenesis of schizophrenia.

Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.

AD-5423 decreased exploratory activity in mice, suppressed conditioned avoidance responding and methamphetamine-induced hyperactivity in mice and rats, antagonized apomorphine-induced gnawing in rats and vomiting in dogs and reduced hostile responses in monkeys.

Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2‐receptor occupancy

This, the first study of its kind, tentatively imputes a role for DA D2‐related activity in left frontal and temporal lobe functions as well as in some non‐verbal abilities mediated more in the right hemisphere in patients with schizophrenia.